ABSTRACT
In patients with terminal glaucoma; both polypropylene AGVs (model S2) and silicone AGVs (model FP7) are safe and effective methods. However the distribution of success rates of silicone AGVs were higher (p<0.05) and it was statistically significant.
Mean follow up was 12.1±3.1 months. Preoperative mean IOP was significantly decreased from 38 mm Hg to 16.33 mmHg in P-AGV group and 41.33 to 12 mm Hg in S-AgV group. In the S-AGV group antiglaucomatous medication was necessary for 1 patient (9.09%) to control IOP. On the other hand in the P-AGV group antiglaucomatous medication was necessary for 3 patients (27.27%) to control IOP. These differences in mean IOP and the number of antiglaucomatous medications were statistically significant (p<0.05). There was no statistically significant difference in BCVA and complications (p>0.05). In the first postoperative day there was shallow anterior chamber in 3 cases of SAGV (27.27%) and 2 cases of PAGV (18.18%). Anterior chamber was reformed with viscoelastic agents in these patients. Minimal hyphema was observed in 4 cases (36.36%) in each group. Fibrin membrane was seen in 1 case of S-AGV group.
22 eyes of 22 patients with medically uncontrolled terminal glaucoma were included in this prospective study which was done between March 2006 and October 2007. Patients were categorized into 2 groups. In the first group, polypropylene AGVs (model S2) (P-AGV group) were implanted to 11 eyes. In the second group, silicone AGVs (model FP7) (S-AGV group) were implanted to 11 eyes. Postoperative best corrected visual acuity (BCVA), intraocular pressure (IOP), antiglaucomatous medication and complications were eva-luated.
To compare the clinical results of silicone and polypropylene Ahmed glaucoma valves (AGVs).